Updates in Diagnosis, Treatment, and Management of Metastatic Uveal Melanoma

Sunandana Chandra, MD, MS, delves into the evolution of the metastatic uveal melanoma treatment landscape and the discussions she has with patients during treatment decision-making.

Editor's note: Tebentafusp is pronounced “teh-BEN-tah-fuhsp.”

EP. 1: How Uveal Melanoma Differs from Cutaneous Melanoma

August 10th 2022

Sunandana Chandra, MD, MS, explains how uveal melanoma is different from cutaneous melanoma, including prevalence, molecular mutations, and survival prognosis after metastasis.

EP. 2: Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

August 10th 2022

Dr Sunandana Chandra describes the typical symptoms that patients with uveal melanoma experience, the prevalent asymptomatic patient population, and how optometrists and ophthalmologists may be involved in the diagnostic process.

EP. 3: Historic and Current Treatment Options for mUM

August 18th 2022

An expert provides an overview of the historical and currently available treatment options in metastatic uveal melanoma (mUM), including the bispecific T-cell receptor immunotherapy tebentafusp (“teh-BEN-tah-fuhsp”).

EP. 4: Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

August 18th 2022

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

EP. 5: Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

August 24th 2022

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.

EP. 6: An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

August 24th 2022

Dr Sunandana Chandra highlights her personal experience in prescribing tebentafusp and other therapies for mUM, and discusses the educational resources and advocacy organizations that she encourages patients to look into to help make an informed decision about their treatment regimens.

EP. 7: Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

September 2nd 2022

An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.

EP. 8: Advice for Patients Living with Metastatic Uveal Melanoma

September 2nd 2022

Sunandana Chandra, MD, MS, closes by sharing advice for patients with metastatic uveal melanoma.